Search | Clinical Trials Finder

Conditions: Type 2 Diabetes
Interventions: exenatide, placebo; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 30 Years to 70 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Rochester, Minnesota • Portland, Oregon

Conditions: Healthy
Interventions: [14C]-HU6; Drug
Lead sponsor: Rivus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Chronic Kidney Disease
Interventions: KBP-5074; Drug
Lead sponsor: KBP Biosciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Healthy
Interventions: BG00012 (dimethyl fumarate), BG00012 placebo, ASA, ASA placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 25 Years to 55 Years
Enrollment: 173 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Atherosclerosis
Interventions: Darapladib, Diltiazem; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses
Interventions: Harmonized supportive care, Etanercept 50 mg sc day 1 and day 4; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 14
States / cities: Phoenix, Arizona • Sacramento, California • Washington D.C., District of Columbia + 11 more

Conditions: Bone Diseases, Infectious
Interventions: Debio 1450; Drug
Lead sponsor: Debiopharm International SA; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: La Mesa, California • Butte, Montana

Conditions: AML/MDS, CMML, Relapse, Refractory Acute Lymphoblastic Leukemia, Relapse Leukemia, Relapsed Adult AML
Interventions: LP-108, LP-108 and azacitidine; Drug
Lead sponsor: Newave Pharmaceutical Inc; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 4
States / cities: Ann Arbor, Michigan • Cincinnati, Ohio • Columbus, Ohio + 1 more

Conditions: Healthy Volunteers
Interventions: [^14C]-LY2157299; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Chronic Hepatitis C
Interventions: Placebo, SCY-635; Drug
Lead sponsor: Scynexis, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 2
States / cities: San Francisco, California • Richmond, Virginia

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Neoplasms, Lymphoma, Malignant
Interventions: E7820; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy Volunteers
Interventions: Centanafadine SR, Centanafadine QD XR; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Healthy Volunteer
Interventions: Ro542-4802/F03 (Reference), Ro542-4802/F07 (Test), Ro542-4802/F08 (Test), Ro542-4802/F14 (Test); Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Dapsone; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Month to 12 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 43
States / cities: Long Beach, California • Los Angeles, California • Oakland, California + 29 more

Conditions: Healthy
Interventions: PF-03382792 Cohort 1, PF-03382792 Cohort 2, PF-03382792, Food Effect cohort, CSF cohort; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Anemia, Sickle Cell, Pneumonia
Interventions: Arginine hydrochloride; Drug
Lead sponsor: UCSF Benioff Children's Hospital Oakland; Other
Eligibility: 5 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 1
States / cities: Oakland, California

Conditions: Healthy, Men, Male Contraception
Interventions: Dimethandrolone-Undecanoate, Levonorgestrel 0.03 MG, Placebo oral capsule; Drug
Lead sponsor: Premier Research; Other
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Torrance, California • Seattle, Washington

Conditions: Multiple Myeloma
Interventions: Ixazomib, Lenalidomide, Dexamethasone; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 16
States / cities: Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 13 more

Conditions: Childhood Mortality
Interventions: Azithromycin, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 1 Month to 60 Months
Enrollment: 190,238 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 2
States / cities: San Francisco, California • Baltimore, Maryland

Conditions: Solid Tumors (Phase 1), RAS Mutation
Interventions: AN9025 oral capsule; Drug
Lead sponsor: Adlai Nortye Biopharma Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Orlando, Florida • Tampa, Florida • Houston, Texas

Conditions: Narcolepsy
Interventions: SEP363856, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 6
States / cities: Orange, California • St. Petersburg, Florida • Atlanta, Georgia + 3 more

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: PEG-interferon alfa-2b, temozolomide; Biological · Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Healthy
Interventions: LY3154207, [14C]-LY3154207; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Madison, Wisconsin

Search by objective public record fields.

How Glargine Insulin, Oral Diabetes Medications and Exenatide May Improve Blood Sugar Control and Weight Gain in Type 2 Diabetics

A Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-HU6

Safety, Tolerability, and Pharmacokinetics of KBP-5074 Following Oral Administration in Chronic Kidney Disease

Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate

Study to Determine the Effect of Repeated Administration of Diltiazem on the Pharmacokinetics of Darapladib (Sb-480848).

NATIENS: Optimal Management and Mechanisms of SJS/TEN

Drug Penetration Into Bone After Repeated Oral Administration of Debio 1450 to Patients Undergoing Hip Replacement Surgery

Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML

A Study of LY2157299 Monohydrate in Healthy Volunteers

Safety, PK and Efficacy of 15 Days of SCY-635 Treatment in Hepatitis C Patients

Adherence to Treatment With Tecfidera™ in Multiple Sclerosis Patients

Dosing and Safety Study of E7820 in Patients With a Malignant Solid Tumor or Lymphoma

A Trial to Compare the Amount of Centanafadine That Enters the Bloodstream for Two Different Formulations of Centanafadine

A Cross-over Study Examining the Bioequivalence of 3 Test Formulations to a Reference Formulation of Alectinib (RO5424802) in Healthy Volunteers

Comparison of Two Dosage Regimens of Oral Dapsone for Prophylaxis of Pneumocystis Carinii Pneumonia in Pediatric HIV Infection

To Evaluate Safety, Tolerability, Plasma Drug Levels And Other Biological Effects In Healthy Volunteers

Arginine Treatment of Acute Chest Syndrome (Pneumonia) in Sickle Cell Disease Patients

Study of Spermatogenesis Suppression With DMAU Alone or With LNG Versus Placebo Alone in Normal Men

A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

Mortality Reduction After Oral Azithromycin: Mortality Study

Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations

This is a Study to Determine the Effect of Multiple Doses of an Investigational Drug, Taken by Mouth, in People With Narcolepsy-cataplexy. Accepting Both Males and Females Ages of 18 Years to 55 Years. This Study Will be Conducted in the US and Will Require Approximately 13 Weeks Participation.

Temozolomide Plus PEG-Interferon Alfa-2B in Treating Patients With Advanced Solid Tumors

Study of LY3154207 in Healthy Participants